samedan logo
 
 
 
spacer
home > ebr > winter 2001 > prevention and cure - intellectual property due diligence and warranties in biotechnology and pharmaceutical technology transfer agreements
PUBLICATIONS
European Biopharmaceutical Review

Prevention and Cure - Intellectual Property Due Diligence and Warranties in Biotechnology and Pharmaceutical Technology Transfer Agreements

Intellectual property (IP) due diligence is a crucial component of any transaction involving the transfer of technology and associated intellectual property rights. Whether you are raising due diligence requests or responding to requests, there are numerous logistical difficulties and potential pitfalls. This article presents a series of 'frequently asked questions' in the area of intellectual property due diligence and provides practical solutions to those questions. Although the terms 'seller' and 'purchaser' will be used in this article, the principles discussed generally apply equally to a licensor and licensee in the context of agreements such as straight licences, collaboration agreements involving cross-licensing, and joint ventures for exploitation of combined technology.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Daniel Pavin, a Solicitor Specialising in Intellectual Property and
Information Technology Law with UK Law Firm Taylor Joynson Garret

Daniel Pavin is a Solicitor specialising in intellectual property and information technology law. Daniel advises a wide range of clients, with a focus on clients in the pharmaceutical, biotechnology and information technology sectors.
Daniel has a degree from Cambridge University, UK, in Computer Science and Physics, and worked as a computer programmer before qualifying as a Solicitor. He has a Diploma in Intellectual Property Law from Bristol University, UK.

spacer
Daniel Pavin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera wins Pharmapack Award in Connected Devices and Wearables category with its body injector platform Symbioze

Symbioze, the smart, high volume and sustainable on-body injector platform developed by Nemera, wins the ‘Connected Devices and Wearables’ Award at Pharmapack 2021 On October 12th, during the Pharmapack Awards Ceremony, a team of industry experts awarded Symbioze, Nemera’s large-volume on-body injector, with the Pharmapack Award in the “Connected Devices and Wearables” category.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement